The Middle East and Africa biofilms treatment market is expected to reach US$ 197.81 million by 2027 from US$ 116.77 million in 2019. The market is estimated to grow with a CAGR of 6.9% from 2020 to 2027.
The growth of the Middle East and Africa biofilms treatment market is driven by the increasing incidence of diabetes and related illnesses, and growing incidences of pressure ulcers amongst geriatric population. However, the concerns regarding the treatment of biofilms is restraining the market growth.
The prevalence of chronic wounds, especially foot ulcers, is increasing among the diabetic population. As per the International Diabetes Federation, in 2017, ~17.3% of the UAE population aged between 20–79 years had type 2 diabetes. Also, over 1 million people are living with diabetes in the UAE, and more than 80,000 adults are expected to undergo a lower extremity amputation. People with diabetes are ten times more likely to undergo amputation at some point in their lifetime. International Federation of Diabetes (IDF) stated that the prevalence of diabetes in 2017 was around 18.5%, accounting for ~3,852,000 total cases of diabetes in UAE. Saudi Arabia has one of the highest diabetic prevalence amongst the Middle Eastern countries. The risk of developing a diabetic foot ulcer is as high as 25% in a diabetes patient. With the increasing diabetic population, it is anticipated that the prevalence of foot ulcers will also rise during 2020–2027. According to the IDF, in 2017, ~1,826,100 cases of diabetes were recorded in South Africa; the prevalence of diabetes in adults was about 5.4% in the country. As the prevalence of diabetes and the same cases is increasing in South Africa, which generates demand for wound care management devices to reduce the risk of slow-healing wounds in diabetic patients. The growing incidence of diabetes and related illnesses, and increasing lower extremity amputation are expected to drive the Middle East and Africa biofilms treatment market during the forecast period.
The COVID-19 pandemic is becoming the most significant challenge in the Middle East and Africa. Region’s fragile and conflict-torn states—such as Iraq (387,121), Sudan (13,653), Iran (479,825), and Yemen (2,047)— are expected to witness serious disruptions as the crisis is hindering imports due to the restriction in the global trade, which is leading to the shortages of medical supplies and other goods, and resulting in a considerable price increase. The Middle East countries is registering a growth in the COVID-19 positive cases—with the UAE registering 100,794 cases, Saudi Arabia reporting 337,243, and South Africa reporting 683,242 confirmed cases. The countries are facing economic crises, which is adversely affecting various businesses such as the healthcare business. These countries are majorly dependent on the imports for healthcare products. The lockdown in various countries globally and the limitations on transport are declining the sales of healthcare products. All these factors are consequently restricting the growth of the Middle East and Africa biofilms treatment market.
Based on product, the Middle East and Africa biofilms treatment market is segmented into debridement equipment, gauzes and dressings, grafts and matrices, and others. The gauzes and dressings segment held the largest share of the market in 2019, and the same segment is anticipated to register the highest CAGR in the market during 2020–2027.
The Middle East and Africa biofilms treatment market, based on wound, is segmented into traumatic and surgical wounds, diabetic foot ulcers, pressure ulcers, venous leg ulcers, and others. In 2019, the traumatic and surgical wounds segment held the largest market share. The same segment is anticipated to register the highest CAGR in the market during the forecast period.
By end user, the Middle East and Africa biofilms treatment market is segmented into hospitals, home care settings, and others. The hospitals segment held the largest share of the market in 2019 and is anticipated to register the highest CAGR in the market from 2020 to 2027.
A few of the primary and secondary sources referred to while preparing the report on the Middle East and Africa biofilms treatment market are the International Diabetes Federation (IDF) and World Health Organization (WHO).